169 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF 34. Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, et al. Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study. Eur Heart J Cardiovasc Pharmacother. 2019;5(2):70–9. 35. Anouassi Z, Atallah B, Alsoud LO, El Nekidy W, Al Mahmeed W, AlJaabari M, et al. Appropriateness of the direct oral anticoagulants dosing in the Middle East Gulf region. J Cardiovasc Pharmacol. 2021;77(2):182–8. 36. Armbruster AL, Buehler KS, Min SH, Riley M, Daly MW. Evaluation of dabigatran for appropriateness of use and bleeding events in a community hospital setting. Am Health Drug Benefits. 2014;7(7):376–84. 37. Ashraf H, Agasthi P, Shanbhag A, Mehta RA, Rattanawong P, Allam M, et al. Long-term clinical outcomes of underdosed direct oral anticoagulants in patients with atrial fibrillation and atrial flutter. Am J Med. 2021;134(6):788–96. 38. Blin P, Dureau-Pournin C, Cottin Y, Bénichou J, Mismetti P, Abouelfath A, et al. Comparative effectiveness and safety of standard or reduced dose dabigatran vs. rivaroxaban in nonvalvular atrial fibrillation. Clin Pharmacol Ther. 2019;105(6):1439–55. 39. Bouget J, Balusson F, Maignan M, Pavageau L, Roy PM, Lacut K, et al. Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study. Br J Clin Pharmacol. 2020;86(12):2519–29. 40. Camm AJ, Cools F, Virdone S, Bassand JP, Fitzmaurice DA, Arthur Fox KA, et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J Am Coll Cardiol. 2020;76(12):1425–36. 41. Chan YH, Chao TF, Chen SW, Lee HF, Yeh YH, Huang YC, et al. Off-label dosing of non– vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. Heart Rhythm. 2020;17(12):2102–10. 42. Chen IC, Chang WT, Hsu PC, Yeh YL, Zheng S, Huang YC, et al. Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation: a retrospective, observational study. Medicine (Baltimore). 2021;100(23):e26272. 43. Cheng WH, Chao TF, Lin YJ, Chang SL, Lo LW, Hu YF, et al. Low-dose rivaroxaban and risks of adverse events in patients with atrial fibrillation. Stroke. 2019;50(9):2574–7. 44. Cho MS, Yun JE, Park JJ, Kim YJ, Lee J, Kim H, et al. Outcomes after use of standard- and low-dose non-vitamin K oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 2019;50:110–8. 45. De Caterina R, Kim YH, Koretsune Y, Wang CC, Yamashita T, Chen C, et al. Safety and effectiveness of edoxaban in atrial fibrillation patients in routine clinical practice: one-year follow-up from the global noninterventional ETNA-AF program. J Clin Med. 2021;10(4):573. 46. Ebrahimi R, Han JK, Goe SH, Treadwell M, Feliciano Z. Patient characteristics and clinical outcomes with low-dose dabigatran. Front Cardiovasc Med. 2017;4:42. 47. Feng Y, Pai CW, Seiler K, Barnes GD. Adverse outcomes associated with inappropriate direct oral anticoagulant starter pack prescription among patients with atrial fibrillation: a retrospective claims-based study. J Thromb Thrombolysis. 2021;51(4):1144–9. 48. Fernández MS, Marín F, Rafols C, Arribas F, Barrios V, Cosín-Sales J, et al. Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). J Comp Eff Res. 2021;10(7):583–93. 49. Forslund T, Wettermark B, Andersen M, Hjemdahl P. Stroke and bleeding with nonvitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. Europace. 2018;20(3):420–8. 50. Gabitova MA, Krupenin PM, Sokolova AA, Napalkov DA, Fomin V V. Safety of non-vitamin K oral anticoagulants in elderly patients with atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2019;15(6):802–5. 8
RkJQdWJsaXNoZXIy MTk4NDMw